Meet the Johnson & Johnson Innovation Team
Texas Medical Center , John P. McGovern Campus , Houston , TX 77021
December 16, 2014 from 12:30 PM to 14:30 PM (CST)
$10 - $35
Johnson & Johnson Innovation recently announced the opening of JLABS @TMC, a partnership with the Texas Medical Center in Houston, TX. Now is your chance to meet the team charged with a new kind of partnering program! Don't miss this opportunity to learn more on the progress of this groundbreaking project. Join us for a chance to be one of the first to hear from Johnson & Johnson Innovation in person.
Over the past few years, Innovators around the US have gotten a chance to know us at JLABS and that has given us an opportunity to interact with you and to think about what else you, the Innovator, need to get your science to the patient. Through our engagement, we continue to evolve in an effort to better meet the needs of the Innovator and ultimately the patient. It is because of you that Johnson & Johnson Innovation (J&J Innovation) created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The J&J Innovation team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
Our corporate venture group, Johnson & Johnson Development Corporation (JJDC), can also fund great science in a more traditional way. Together our teams can provide you the best possible chance of taking your solution to the people who need it the most.
On December 16, hear from Sarah Bodary - Senior Director, New Ventures at J&J Innovation - Thorsten Melcher - Senior Director, New Ventures and Partnerships at J&J Innovation - and Arturo Molina - VP of Oncology Innovation at J&J Innovation. Sarah, Thorsten and Arturo will provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives. Don't miss this opportunity to learn more on the progress of this groundbreaking project. Join us for a chance to be one of the first to hear from the Johnson & Johnson Innovation Center in person.
11:30am | Registration and Lunch
12:00pm | Presentation and Q&A
1:30pm | Program closes
J&J Innovation Participating Representatives:
Sarah Bodary, Ph.D. | Senior Director, New Ventures, J&J Innovation read bio»
Thorsten Melcher, Ph.D. | Senior Director, New Ventures and Partnerships, J&J Innovation read bio»
Arturo Molina, M.D. | VP of Oncology Innovation, J&J Innovation read bio»
Joe Martin | Health Care and Tech Reporter, Houston Business Journal read bio»
Sarah Bodary, Ph.D. | Senior Director, New Ventures, J&J Innovation
Sarah is Senior Director of New Ventures at Johnson and Johnson Innovation, California. She is experienced in drug and business development as well as company creation and venture investing.
Previously, Sarah was a Venture Partner as SV Life Sciences where as a member of the therapeutic investing team, she was involved in evaluating investment opportunities, starting Arsanis Biosciences and served on the board of Itero Biopharmaceuticals. Prior to venture capital Sarah was a member of the management team at Schering Plough Biopharma as a Director of Business Development, where she helped transform DNAX Research Institute into the early stage biologics engine for Schering Plough and managed the biologics business development efforts.
As a scientist at Genentech, Sarah led numerous therapeutic product teams targeting Integrins, from target identification and validation through Phase 1, and was a member of the Raptiva antibody late stage development, BLA filing and launch teams. She is an author on numerous peer reviewed journals and an inventor on over 30 patents.
Sarah earned her B.Sc. in Molecular Biology at the University of Edinburgh, Scotland and a Ph.D. in Molecular Biology at the University of Lausanne/ISREC , Switzerland. She was a postdoctoral scholar at UCSF in Molecular Neurobiology.
|Connect with Sarah:|
Thorsten Melcher, Ph.D. | Senior Director, New Ventures and Partnerships, J&J Innovation
Thorsten is Senior Director for New Ventures and Partnerships Johnson & Johnson Innovation, California. He focuses on establishing and guiding collaborative partnerships with academic centers and biotech companies, and on facilitating new company formation by internal and external entrepreneurs.
Previously, Thorsten led the biomedical efforts at Varian Medical Systems, an instrumentation and software company in radiation oncology. At Varian, he established a spin-out company to integrate radiotherapy with targeted cancer therapeutics. Before Varian, Thorsten was co-founder and was serving in several R&D, business development and operational and roles at AGY Therapeutics, EnVivo Pharmaceuticals and Saegis Pharmaceuticals. These California-based start-up companies focused on discovery and early development in various neurological and mental disorders. Thorsten's scientific experience spans therapeutics in neuroscience and oncology, companion diagnostics and early clinical development. On the business side, he focuses on licensing and collaborative arrangements and private financings.
Thorsten received his MS in Biochemistry from the University and Medical School in Hannover, Germany and his Ph.D. in Molecular Neurobiology from the Center of Molecular Biology at the University of Heidelberg, Germany. He was a postdoctoral fellow at the University of California, San Francisco.
|Connect with Thorsten:|
Arturo Molina, M.D. | VP of Oncology Innovation, J&J Innovation
Arturo is Vice President, Oncology Scientific Innovation at Johnson & Johnson Innovation, California. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies.
Previously he was the Vice President Clinical Research, Oncology, where he was responsible for the clinical development and registration-directed studies of ZYTIGA® (abiraterone acetate) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Prior to this role he was the Chief Medical Officer and Executive Vice-President at Cougar Biotechnology, which was acquired by The Johnson & Johnson Family of Companies.
Before joining Cougar Biotechnology, Dr. Molina worked at IDEC as Senior Director, Medical Affairs, ultimately becoming Department Head, Oncology Clinical Development for Biogen-IDEC. In collaboration with Genentech, he led clinical Supplemental Biologics License Application filing activities resulting in the U.S. Food and Drug Administration approval of Rituxan®.
Dr. Molina was a faculty staff physician in Hematology/Bone Marrow Transplantation and Medical Oncology/Therapeutics Research at the City of Hope (COH) Comprehensive Cancer Center, where he became an Adjunct Professor , member of the COH Medical Group Board of Directors and President-Elect of the City of Hope Medical Staff.
Dr. Molina received his medical degree and master's in Physiology from Stanford University School of Medicine, and continued at Stanford for Residency in Internal Medicine and Fellowships in Medical Oncology, Biological Science, and Bone Marrow Transplantation. Dr. Molina was an undergraduate at the University of Texas at Austin where he received a B.S. in Zoology (Honors) and B.A. in Psychology (High Honors).
|Connect with Arturo:|
Joe Martin | Health Care and Tech Reporter, Houston Business Journal
Joe Martin joined the Houston Business Journal in June as the paper's health care and technology reporter. Prior to joining HBJ, he attended Arizona State University, where he earned a degree in journalism with a minor in business. He interned at the Phoenix Business Journal for eight months, where he covered topics ranging from health care to sports business. He also served as he editor in chief for the Downtown Devil, an online publication that focused on downtown Phoenix. He is a native of Springfield, Illinois.
|Connect with Joe:|